Description

Rolapitant CAS NO 552292-08-7 is a highly selective and long-acting neurokinin-1 (NK-1) receptor antagonist. This compound is of significant commercial and therapeutic importance for its role in preventing chemotherapy-induced nausea and vomiting (CINV). It is primarily required by pharmaceutical manufacturers, research institutions, and contract development and manufacturing organizations (CDMOs) involved in the production of antiemetic drugs and advanced oncological therapeutics.

Application

• Pharmaceutical Active Ingredient (API): Core component in the formulation of delayed-phase CINV prevention medications.
• Oncological Supportive Care: Manufacture of antiemetic drugs used in conjunction with highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens.
• Drug Development & Research: Critical reference standard and intermediate in preclinical and clinical research for new antiemetic therapies.
• Finished Dosage Form Production: Used in the production of oral solid dosage forms, such as tablets and capsules.
• Contract Manufacturing: Supplied to CDMOs for the production of branded and generic pharmaceutical products.
• Neurological Research: Investigated for potential applications in substance use disorders and other conditions mediated by the NK-1 receptor pathway.

Basic Information

Product Name	Rolapitant
CAS No.	552292-08-7
Molecular Formula	C31H37F2N3O3
Molecular Weight	537.64 g/mol
Synonyms	SCH 619734; Varubi; (5S,8S)-8-({(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}methyl)-8-phenyl-1,7-diazaspiro[4.5]decan-2-one; Rolapitant Hydrobromide (salt form precursor); NK-1 Receptor Antagonist; Neurokinin-1 Antagonist; Antiemetic Agent
EINECS	Contact for details

Quality Control

Our Rolapitant is manufactured under strict quality management systems. Each batch undergoes comprehensive analytical testing to ensure it meets stringent specifications for identity, purity, and potency, aligning with ICH guidelines. A detailed Certificate of Analysis (COA) is provided with every shipment, documenting results for assay, related substances, residual solvents, and other critical parameters. We support compliance with cGMP, FDA, and other major global regulatory standards for pharmaceutical intermediates and APIs.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept under dry conditions to prevent degradation. For long-term storage, consider using desiccants.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to reference standard
Identification (HPLC)	Conforms to reference standard
Assay (HPLC)	98.0% - 102.0%
Related Substances (HPLC)	Total impurities ≤ 1.0% Any single impurity ≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Heavy Metals	≤ 20 ppm
Loss on Drying	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.